Twice-Daily Radiation Associated With Better Patient-Reported Outcomes in Limited-Stage Small Cell Lung Cancer

Clinical Summary: 

• Design/Population: NRG-LU005 randomized 544 patients to standard platinum/etoposide chemoradiation with either 45 Gy of twice-daily or 66 Gy of once-daily thoracic radiation, with or without atezolizumab. This planned analysis evaluated longitudinal patient-reported outcomes.
• Key Outcomes: Adding atezolizumab did not significantly reduce clinically meaningful decline in FACT-TOI scores at the prespecified 15-month assessment, with similar EQ-5D-5L and fatigue outcomes between treatment arms. Twice-daily radiation was associated with better FACT-TOI outcomes than once-daily radiation across all assessed time points. 
• Clinical Relevance: The findings do not demonstrate a 15-month patient-reported quality-of-life advantage from adding atezolizumab to chemoradiation but suggest that twice-daily thoracic radiation may be associated with more favorable longitudinal patient-reported outcomes than once-daily radiation. Because patients were not randomized by radiation schedule, this finding requires cautious interpretation.

A planned patient-reported outcome analysis from the NRG-LU005 trial showed that adding atezolizumab to chemoradiation did not significantly reduce clinically meaningful decline in quality-of-life–related outcomes at 15 months, while twice-daily thoracic radiation was associated with more favorable longitudinal patient-reported outcomes than once-daily radiation. 

In this trial, 544 patients with limited-stage small cell lung cancer were randomized to receive standard chemoradiation with platinum/etoposide plus thoracic radiation, with or without atezolizumab beginning during cycle 2 of chemotherapy. Thoracic radiation consisted of either 45 Gy delivered twice daily, or 66 Gy delivered once daily. 

The prespecified hypothesis for the patient-reported outcome analysis was that adding atezolizumab would reduce clinically meaningful decline in longer-term patient-reported outcome at 15 months, measured using validated instruments, including the Functional Assessment of Cancer Therapy–Trial Outcome Index (FACT-TOI). Additional assessments included the EQ-5D-5L and PROMIS-Fatigue instruments. 

Patient-reported outcomes were collected at baseline, the end of chemoradiation, and at 3, 6, 15, and 21 months, with EQ-5D-5L assessments continuing through 24 months. Baseline patient-reported outcome compliance exceeded 85% at baseline and stabilized between 60% and 68% through 21 months. 

At the prespecified 15-month assessment, clinically meaningful decline in FACT-TOI was not significantly different between patients who received atezolizumab and those treated with chemoradiation alone. EQ-5D-5L and PROMIS-Fatigue outcomes were also similar between treatment groups. 

A later difference emerged at 21 months, when fewer patients receiving atezolizumab experienced clinically meaningful decline in FACT-TOI. In multivariable analysis, immunotherapy was significantly associated with a lower likelihood of FACT-TOI decline at this time point, although this was not the prespecified primary patient-reported outcome assessment.

Radiation schedule was more consistently associated with patient-reported outcomes. Patients receiving twice-daily radiation had better FACT-TOI outcomes than those receiving once-daily radiation across all assessed timepoints. In multivariable analysis, twice-daily radiation significantly predicted a lower likelihood of clinically meaningful FACT-TOI at the end of chemoradiation and at 15 and 21 months. 

Other factors associated with a lower likelihood of FACT-TOI decline included performance status at the end of chemoradiation and cisplatin use at 15 months.

The radiation-schedule findings complement the exploratory overall survival findings from NRG-LU005, which showed longer survival with twice-daily compared with once-daily radiation. However, patients were not randomized according to radiation schedule, limiting conclusions about whether twice-daily treatment itself produced the more favorable patient-reported outcome trajectory.

Overall, the planned analysis did not support the hypothesis that adding atezolizumab to chemoradiation would significantly reduce clinically meaningful patient-reported decline at 15 months.

“The addition of atezolizumab to chemoradiation was not associated with a significant change in [clinically meaningful decline] in FACT-TOI at 15 months, with similar EQ-5D-5L and fatigue scores,” concluded study investigators. “While not randomized for [radiotherapy]-schedule, this analysis suggests that [twice-daily radiotherapy] was associated with a consistently more favorable [patient reported outcome] trajectory.” 

Source: 

Movsas B, Hu C, Higgins KA, et al. Comprehensive patient reported outcomes (PROs) from NRG Oncology/Alliance LU005: A randomized trial of chemoradiation +/- atezolizumab In limited-stage small cell lung cancer. J Thorac Oncol. Published online: July 29, 2026:104117. doi: 10.1016/j.jtho.2026.104117